Oncology

Back to articles

Pemetrexed for maintenance treatment of metastatic lung cancer

KEY POINT

On July 2, 2009, FDA approved pemetrexed disodium injection (Alimta–Eli Lilly) for maintenance treatment of locally advanced or metastatic nonsquamous nonsmall cell lung cancer (NSCLC) in patients whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy.

SOURCES

FDA Center for Drug Evaluation and Research Web site. Pemetrexed injection. Pemetrexed (Alimta injection) package insert. Eli Lilly. Indianapolis, IN. July 2009.